{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:50Z","timestamp":1772119250633,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["No.1840190390"],"award-info":[{"award-number":["No.1840190390"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Follicular lymphoma (FL) is a common indolent B-cell lymphoma with heterogeneous clinical behavior. Prognostic data from Chinese real-world populations remain Limited. We retrospectively analyzed 118 patients with newly diagnosed FL treated at our center from January 2022 to December 2024. Clinical features, laboratory indicators, immune markers, and treatment responses were evaluated. Survival outcomes were analyzed using Kaplan\u2013Meier and Cox regression methods. The follow-up ended on January 31, 2025, with a median follow-up duration of 11.2\u00a0months (range, 1.1\u201336.0\u00a0months). The 2-year overall survival (OS) and progression-free survival (PFS) rates were 90.1% and 69.7%, respectively. The overall complete response (CR) rate was 60.2%. In univariate analysis, several factors including pathological grade 3B\/composite histology, B symptoms, low NK cell percentage (&lt;\u20098%), low CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell levels (&lt;\u200930%), CD5 positivity, CD10 negativity, and MUM1 positivity were significantly associated with poor OS and\/or PFS. Multivariate Cox regression revealed that pathological grade 3B\/composite histology was an independent risk factor for PFS (HR 2.933,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.035), while NK cell percentage\u2009&lt;\u20098% independently predicted worse OS (HR 0.067,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005). This study validates the prognostic significance of pathological grade and NK cell levels in a Chinese real-world FL population. Peripheral blood NK cell percentage may serve as a clinically useful biomarker for host immune status and prognosis. The findings support further investigation into immune-based prognostic markers and therapeutic strategies in FL.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06617-2","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T23:52:04Z","timestamp":1758325924000},"page":"5257-5271","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China"],"prefix":"10.1007","volume":"104","author":[{"given":"Yang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzhong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"6617_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","volume":"63","author":"G Kanas","year":"2022","unstructured":"Kanas G, Ge W, Quek RGW et al (2022) Epidemiology of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in the United States and Western Europe: population-level projections for2020\u20132025. Leuk Lymphoma 63:54\u201363","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"6617_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"7","key":"6617_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10(7):74","journal-title":"Blood Cancer J"},{"issue":"7","key":"6617_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10(7):74","journal-title":"Blood Cancer J"},{"key":"6617_CR5","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-grade lymphoma study group. Blood 106:3725\u20133732","journal-title":"Blood"},{"key":"6617_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J et al (2016) Obinutuzumab plus bendamustine versus bendamustinemonotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081\u20131093","journal-title":"Lancet Oncol"},{"issue":"23","key":"6617_CR7","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"issue":"32","key":"6617_CR8","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","volume":"26","author":"AJ Al-Tourah","year":"2008","unstructured":"Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(32):5165\u20135169","journal-title":"J Clin Oncol"},{"key":"6617_CR9","doi-asserted-by":"publisher","first-page":"626035","DOI":"10.1155\/2012\/626035","volume":"2012","author":"AJ Ambinder","year":"2012","unstructured":"Ambinder AJ, Shenoy PJ, Malik N, Maggioncalda A, Nastoupil LJ, Flowers CR (2012) Exploring risk factors for follicular lymphoma. Adv Hematol 2012:626035","journal-title":"Adv Hematol"},{"issue":"27","key":"6617_CR10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068","journal-title":"J Clin Oncol"},{"issue":"15","key":"6617_CR11","doi-asserted-by":"publisher","first-page":"1426064","DOI":"10.3389\/fimmu.2024.1426064","volume":"17","author":"J Tang","year":"2024","unstructured":"Tang J, Shang C, Chang Y et al (2024) Peripheral PD-1(+)NK cells could predict the 28-day mortality in sepsis patients. Front Immunol 17(15):1426064","journal-title":"Front Immunol"},{"issue":"6","key":"6617_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/ajh.23708","volume":"89","author":"C Nabhan","year":"2014","unstructured":"Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, Evens AM (2014) The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras. Am J Hematol 89(6):633\u2013638","journal-title":"Am J Hematol"},{"issue":"5","key":"6617_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D et al (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"1","key":"6617_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL et al (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132(1):49\u201358","journal-title":"Blood"},{"issue":"2","key":"6617_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajh.24937","volume":"93","author":"A Freedman","year":"2018","unstructured":"Freedman A (2018) Follicular lymphoma: 2018 update on diagnosis and management. Am J Hematol 93(2):296\u2013305","journal-title":"Am J Hematol"},{"issue":"7","key":"6617_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/bloodadvances.2019032136","volume":"3","author":"S Alig","year":"2019","unstructured":"Alig S, Jurinovic V, Pastore A, Haebe S, Schmidt C, Zoellner AK, Dreyling M, Unterhalt M, Hoster E, Hiddemann W et al (2019) Impact of age on clinical risk scores in follicular lymphoma. Blood Adv 3(7):1033\u20131038","journal-title":"Blood Adv"},{"issue":"47","key":"6617_CR17","doi-asserted-by":"publisher","first-page":"76934","DOI":"10.18632\/oncotarget.12734","volume":"7","author":"S Seo","year":"2016","unstructured":"Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW et al (2016) Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget 7(47):76934\u201376943","journal-title":"Oncotarget"},{"issue":"4","key":"6617_CR18","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1007\/s12032-012-0176-1","volume":"29","author":"M Dehghani","year":"2012","unstructured":"Dehghani M, Sharifpour S, Amirghofran Z, Zare HR (2012) Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin\u2019s lymphoma patients. Med Oncol 29(4):2364\u20132371","journal-title":"Med Oncol"},{"issue":"10","key":"6617_CR19","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1111\/cas.13020","volume":"107","author":"XY Zhang","year":"2016","unstructured":"Zhang XY, Xu J, Zhu HY, Wang Y, Wang L, Fan L, Wu YJ, Li JY, Xu W (2016) Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci 107(10):1471\u20131476","journal-title":"Cancer Sci"},{"issue":"1","key":"6617_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4143\/crt.2018.010","volume":"51","author":"YP Zhang","year":"2019","unstructured":"Zhang YP, Zhang R, Zhu HY, Wang L, Wu YJ, Liang JH, Shi WY, Liu H, Xu W, Li JY (2019) Circulating low absolute CD4+ T cell counts may predict poor prognosis in extranodal NK\/T-cell lymphoma patients treating with pegaspargase-based chemotherapy. Cancer Res Treat 51(1):368\u2013377","journal-title":"Cancer Res Treat"},{"issue":"9","key":"6617_CR21","doi-asserted-by":"publisher","first-page":"12589","DOI":"10.1007\/s13277-016-5124-9","volume":"37","author":"L He","year":"2016","unstructured":"He L, Liang JH, Wu JZ, Li Y, Qin SC, Miao Y, Wu YJ, Wang Y, Wang L, Fan L et al (2016) Low absolute CD4+ T cell counts in peripheral blood are associated with inferior survival in follicular lymphoma. Tumour Biol 37(9):12589\u201312595","journal-title":"Tumour Biol"},{"key":"6617_CR22","doi-asserted-by":"publisher","first-page":"513702","DOI":"10.1155\/2012\/513702","volume":"2012","author":"JM McDaniel","year":"2012","unstructured":"McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK (2012) Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012:513702","journal-title":"Adv Hematol"},{"issue":"7","key":"6617_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/annonc\/mdm110","volume":"18","author":"A Plonquet","year":"2007","unstructured":"Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M et al (2007) Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2\u20133 diffuse large B-cell lymphoma. Ann Oncol 18(7):1209\u20131215","journal-title":"Ann Oncol"},{"issue":"18","key":"6617_CR24","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1073\/pnas.92.18.8200","volume":"92","author":"JL Schultze","year":"1995","unstructured":"Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM (1995) Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci U S A 92(18):8200\u20138204","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"6617_CR25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","volume":"37","author":"D Shafer","year":"2013","unstructured":"Shafer D, Smith MR, Borghaei H, Millenson MM, Li T, Litwin S, Anad R, Al-Saleem T (2013) Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma. Leuk Res 37(10):1213\u20131215","journal-title":"Leuk Res"},{"issue":"11","key":"6617_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.autrev.2012.02.007","volume":"11","author":"RA Mageed","year":"2012","unstructured":"Mageed RA, Garaud S, Taher TE, Parikh K, Pers JO, Jamin C, Renaudineau Y, Youinou P (2012) CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. Autoimmun Rev 11(11):795\u2013798","journal-title":"Autoimmun Rev"},{"key":"6617_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0065-2776(08)60663-X","volume":"47","author":"TJ Kipps","year":"1989","unstructured":"Kipps TJ (1989) The CD5 B cell. Adv Immunol 47:117\u2013185","journal-title":"Adv Immunol"},{"issue":"8","key":"6617_CR28","doi-asserted-by":"publisher","first-page":"5615","DOI":"10.18632\/oncotarget.3479","volume":"6","author":"ZY Xu-Monette","year":"2015","unstructured":"Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y et al (2015) Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 6(8):5615\u20135633","journal-title":"Oncotarget"},{"issue":"4","key":"6617_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/ejh.12847","volume":"98","author":"B Thakral","year":"2017","unstructured":"Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, Khoury JD, Hu S, Xu J, Loghavi S et al (2017) Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol 98(4):415\u2013421","journal-title":"Eur J Haematol"},{"issue":"8","key":"6617_CR30","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3324\/haematol.12810","volume":"93","author":"M Yamaguchi","year":"2008","unstructured":"Yamaguchi M, Nakamura N, Suzuki R et al (2008) De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 93(8):1195\u20131202","journal-title":"Haematologica"},{"issue":"4","key":"6617_CR31","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/10428194.2021.2002317","volume":"63","author":"A Soleimani","year":"2022","unstructured":"Soleimani A, Navarro A, Liu D et al (2022) CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. Leuk Lymphoma 63(4):911\u2013917","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"6617_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/pin.12145","volume":"64","author":"H Miyoshi","year":"2014","unstructured":"Miyoshi H, Sato K, Yoshida M et al (2014) CD5-positive follicular lymphoma characterized by CD25, MUM1, low frequency of t(14;18) and poor prognosis. Pathol Int 64(3):95\u2013103","journal-title":"Pathol Int"},{"issue":"6","key":"6617_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/modpathol.2015.42","volume":"28","author":"Yu Li","year":"2015","unstructured":"Li Yu, Shimin Hu, Zuo Z et al (2015) CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol 28(6):787\u2013798","journal-title":"Mod Pathol"},{"issue":"15","key":"6617_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1336310","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Xiao Y, An X, Luo L, Gong K, Yu D (2024) A comprehensive review of the literature on CD10: its function, clinical application, and prospects. Front Pharmacol 8(15):1336310","journal-title":"Front Pharmacol"},{"issue":"1","key":"6617_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mce.2013.09.027","volume":"382","author":"A Thong","year":"2014","unstructured":"Thong A, M\u00fcller D, Feuerstacke C, Mietens A, Stammler A, Middendorff R (2014) Neutral endopeptidase (Cd10) is abundantly expressed in the epididymis and localized to a distinct population of epithelial cells\u2013its relevance for CNP degradation. Mol Cell Endocrinol 382(1):234\u2013243","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"6617_CR36","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/PAI.0000000000001208","volume":"32","author":"A Sadeghipour","year":"2024","unstructured":"Sadeghipour A, Taha SR, Zadeh MS et al (2024) Expression and clinical significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in diffuse large B cell lymphoma patients. Appl Immunohistochem Mol Morphol 32(7):309\u2013321","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"6617_CR37","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","volume":"98","author":"B Bisig","year":"2013","unstructured":"Bisig B, de Reynies A, Bonnet C, Sujobert P, Rickman DS, Marafioti T, Delsol G, Lamant L, Gaulard P, de Leval L (2013) CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica 98(8):1250\u20131258","journal-title":"Haematologica"},{"issue":"3","key":"6617_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.leu.2401696","volume":"14","author":"K Tsuboi","year":"2000","unstructured":"Tsuboi K, Iida S, Inagaki H, Kato M, Hayami Y, Hanamura I, Miura K, Harada S, Kikuchi M, Komatsu H et al (2000) MUM1\/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 14(3):449\u2013456","journal-title":"Leukemia"},{"issue":"1","key":"6617_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275\u2013282","journal-title":"Blood"},{"issue":"6","key":"6617_CR40","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.7150\/jca.17358","volume":"8","author":"MH Heo","year":"2017","unstructured":"Heo MH, Park HY, Ko YH, Kim WS, Kim SJ (2017) IRF4\/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer 8(6):1018\u20131024","journal-title":"J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06617-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:19:09Z","timestamp":1763194749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6617"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06617-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6213475\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Traditional Chinese Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}